HJLI Share Price | enVVeno Medical Corp. Stock Analysis & Recommendation

Q: How big is enVVeno Medical Corp.?

Market Cap: As of Jun 18, enVVeno Medical Corp. has a market capitalization of 75.23 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, enVVeno Medical Corp. reported net sales of 0.00 million and a net profit of -21.33 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 42.16 million and total assets of 44.95 million.

Q: What does enVVeno Medical Corp. do?

Overview:enVVeno Medical Corp. is a development stage medical device company in the Pharmaceuticals & Biotechnology industry, focused on creating biologic-based solutions for patients with cardiovascular and venous diseases.Financial Snapshot:Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) Market cap: USD 75.23 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -55.00% Price to Book: 1.96 Contact Details:Address: 70 Doppler, IRVINE CA 92618-4306 Tel: 1 949 2612900 Fax: 1 949 2612992 Website: http://www.hancockjaffe.com/

Q: Is enVVeno Medical Corp. technically bullish or bearish?

As of 3 September 2025, the technical trend for enVVeno Medical Corp. has changed from sideways to mildly bearish. The current stance is bearish overall, with key indicators supporting this view including bearish MACD readings on both weekly and monthly time frames, bearish moving averages on a daily basis, and bearish signals from Dow Theory and KST. While the weekly and monthly RSI readings are bullish, they are overshadowed by the overall bearish trend. The stock has significantly underperformed compared to the S&P 500, with a 1-month return of -81.29% versus 2.33% for the index, and a 1-year return of -81.67% compared to 17.14% for the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

8.9 k

Shareholding (Sep 2025)

FII

3.92%

Held by 15 FIIs

DII

90.08%

Held by 7 DIIs

Promoter

0.00%

How big is enVVeno Medical Corp.?

22-Jun-2025

As of Jun 18, enVVeno Medical Corp. has a market capitalization of 75.23 million, with net sales of 0.00 million and a net profit of -21.33 million over the last four quarters. The company reported shareholder's funds of 42.16 million and total assets of 44.95 million as of Dec 24.

View full answer

What does enVVeno Medical Corp. do?

22-Jun-2025

enVVeno Medical Corp. is a development stage medical device company focused on biologic-based solutions for cardiovascular and venous diseases. As of March 2025, it has a market cap of $75.23 million and reported a net profit loss of $5 million.

View full answer

Is enVVeno Medical Corp. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, enVVeno Medical Corp. shows a mildly bearish trend, supported by bearish MACD and moving averages, despite bullish RSI readings, and has significantly underperformed the S&P 500 with a 1-month return of -81.29% and a 1-year return of -81.67%.

View full answer

Compare enVVeno Medical Corp. with Similar Stocks

Avinger, Inc.Kewaunee Scientific Corp.HeartBeam, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 6 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.04

Return on Equity

-73.13%

Price to Book

0.21

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

246.3%

6 Months

216.95%

1 Year

98.94%

2 Years

248.88%

3 Years

147.35%

4 Years

48.77%

5 Years

-20.43%

enVVeno Medical Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-212.07%

EBIT to Interest (avg)

-20.69

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

43.03%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.75

EV to EBIT

-1.23

EV to EBITDA

-1.26

EV to Capital Employed

-28.59

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-55.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (6%)

Foreign Institutions

Held by 15 Foreign Institutions (3.92%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 19.64% vs -12.00% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.80",
          "val2": "-6.00",
          "chgp": "20.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.50",
          "val2": "-5.60",
          "chgp": "19.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.23% vs 4.86% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.30",
          "val2": "-24.70",
          "chgp": "5.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.50",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.80",
          "val2": "-23.50",
          "chgp": "7.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.80

-6.00

20.00%

Interest

0.00

Exceptional Items

-0.00

0.00

Consolidate Net Profit

-4.50

-5.60

19.64%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 19.64% vs -12.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-23.30

-24.70

5.67%

Interest

0.00

Exceptional Items

-0.00

0.50

-100.00%

Consolidate Net Profit

-21.80

-23.50

7.23%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.23% vs 4.86% in Dec 2023

All Annual Results

Company CV

About enVVeno Medical Corp.

enVVeno Medical Corp.

Pharmaceuticals & Biotechnology

Hancock Jaffe Laboratories, Inc. is a development stage medical device company. The Company is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The Company is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.

Company Coordinates

Company Details

70 Doppler , IRVINE CA : 92618-4306

Tel: 1 949 2612900

http://www.hancockjaffe.com/

Registrar Details

enVVeno Medical Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is enVVeno Medical Corp.?

Watch in Real-Time

What does enVVeno Medical Corp. do?

Is enVVeno Medical Corp. technically bullish or bearish?

Compare enVVeno Medical Corp. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About enVVeno Medical Corp.

Company Coordinates